Immunocore Holdings plc Basic Shares Outstanding (Weighted Average)
Immunocore Holdings plc (IMCR) reported Basic Shares Outstanding (Weighted Average) of 50.97 million shares for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:WeightedAverageNumberOfSharesOutstandingBasic · last filed 2026-08-06
- Immunocore Holdings plc weighted average number of shares outstanding, basic for the quarter ending 2026-06-30 was 50.97M shares, a 1.35% increase year-over-year.
- Immunocore Holdings plc weighted average number of shares outstanding, basic for the quarter ending 2026-03-31 was 50.75M shares, a 1.33% increase year-over-year.
- Immunocore Holdings plc weighted average number of shares outstanding, basic for the quarter ending 2025-12-31 was 50.59M shares, a 1.09% increase year-over-year.
- Immunocore Holdings plc weighted average number of shares outstanding, basic for the quarter ending 2025-09-30 was 50.40M shares, a 0.76% increase year-over-year.
- Immunocore Holdings plc weighted average number of shares outstanding, basic for fiscal 2025 was 50.35M shares, a 0.71% increase from fiscal 2024.
- Immunocore Holdings plc weighted average number of shares outstanding, basic for fiscal 2024 was 49.99M shares, a 2.25% increase from fiscal 2023.
- Immunocore Holdings plc weighted average number of shares outstanding, basic for fiscal 2023 was 48.89M shares, a 6.94% increase from fiscal 2022.
- Immunocore Holdings plc weighted average number of shares outstanding, basic for fiscal 2022 was 45.71M shares, a 7.59% increase from fiscal 2021.
| Period end | Weighted Average Number of Shares Outstanding, Basic 3 month | Weighted Average Number of Shares Outstanding, Basic 6 month | Weighted Average Number of Shares Outstanding, Basic 9 month | Weighted Average Number of Shares Outstanding, Basic 12 month |
|---|---|---|---|---|
| 2026-06-30 | 50.97M shares 10-Q · filed 2026-08-06 | 50.87M shares 10-Q · filed 2026-08-06 | 50.77M shares derived: average of 3 quarters · filed 2026-08-06 | 50.68M shares derived: average of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | 50.75M shares 10-Q · filed 2026-05-06 | 50.67M shares derived: average of 2 quarters · filed 2026-05-06 | 50.58M shares derived: average of 3 quarters · filed 2026-05-06 | 50.51M shares derived: average of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | 50.59M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | 50.50M shares derived: average of 2 quarters · filed 2026-02-25 | 50.43M shares derived: average of 3 quarters · filed 2026-08-06 | 50.35M shares 10-K · filed 2026-02-25 |
| 2025-09-30 | 50.40M shares 10-Q · filed 2025-11-06 | 50.35M shares derived: average of 2 quarters · filed 2026-08-06 | 50.26M shares 10-Q · filed 2025-11-06 | 50.21M shares derived: average of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | 50.29M shares 10-Q · filed 2026-08-06 | 50.19M shares 10-Q · filed 2026-08-06 | 50.14M shares derived: average of 3 quarters · filed 2026-08-06 | 50.11M shares derived: average of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | 50.09M shares 10-Q · filed 2026-05-06 | 50.07M shares derived: average of 2 quarters · filed 2026-05-06 | 50.05M shares derived: average of 3 quarters · filed 2026-05-06 | 50.04M shares derived: average of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | 50.05M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | 50.04M shares derived: average of 2 quarters · filed 2026-02-25 | 50.03M shares derived: average of 3 quarters · filed 2026-02-25 | 49.99M shares 10-K · filed 2026-02-25 |
| 2024-09-30 | 50.02M shares 10-Q · filed 2025-11-06 | 50.02M shares derived: average of 2 quarters · filed 2025-11-06 | 49.97M shares 10-Q · filed 2025-11-06 | 49.86M shares derived: average of 4 quarters · filed 2026-02-25 |
| 2024-06-30 | 50.01M shares 10-Q · filed 2025-08-07 | 49.94M shares 10-Q · filed 2025-08-07 | 49.81M shares derived: average of 3 quarters · filed 2026-02-25 | 49.64M shares derived: average of 4 quarters · filed 2026-02-25 |
| 2024-03-31 | 49.88M shares 10-Q · filed 2025-05-07 | 49.71M shares derived: average of 2 quarters · filed 2026-02-25 | 49.52M shares derived: average of 3 quarters · filed 2026-02-25 | 49.31M shares derived: average of 4 quarters · filed 2026-02-25 |
| 2023-12-31 | 49.54M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | 49.34M shares derived: average of 2 quarters · filed 2026-02-25 | 49.12M shares derived: average of 3 quarters · filed 2026-02-25 | 48.89M shares 10-K · filed 2026-02-25 |
| 2023-09-30 | 49.13M shares 10-Q · filed 2024-11-06 | 48.91M shares derived: average of 2 quarters · filed 2024-11-06 | 48.67M shares 10-Q · filed 2024-11-06 | |
| 2023-06-30 | 48.69M shares 10-Q · filed 2024-08-08 | 48.44M shares 10-Q · filed 2024-08-08 | ||
| 2023-03-31 | 48.18M shares 10-Q · filed 2024-05-08 | |||
| 2022-12-31 | 45.71M shares 10-K · filed 2025-02-26 | |||
| 2021-12-31 | 42.49M shares 10-K · filed 2024-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |